Empagliflozin 10 mg is an SGLT2 (sodium-glucose cotransporter-2) inhibitor used primarily to manage Type 2 diabetes mellitus. It works by reducing glucose reabsorption in the kidneys, causing excess glucose to be eliminated through urine and thereby lowering blood glucose levels. Empagliflozin is also used in appropriate patients to reduce the risk of cardiovascular death and hospitalization for heart failure, and to reduce the risk of worsening kidney disease and related cardiovascular outcomes in adults with chronic kidney disease.
Indications :
- Type 2 diabetes mellitus, along with diet and exercise, to improve glycemic control.
- Reduction of cardiovascular death in appropriate patients with Type 2 diabetes and established cardiovascular disease.
- Reduction of cardiovascular death and hospitalization for heart failure in adults with heart failure.
- Reduction of risk of sustained decline in kidney function and end-stage kidney disease in appropriate adults with chronic kidney disease.
Common Side Effects :
- Increased urination
- Urinary tract infections
- Genital fungal/yeast infections
- Increased thirst
- Dehydration or dizziness, particularly due to fluid loss
- Low blood pressure, especially in susceptible patients
Urinary and genital infections are among the recognized adverse effects of empagliflozin.
Storage :
Store at 20–25°C (68–77°F), with permitted excursions between 15–30°C (59–86°F). Keep the tablets in a well-closed container, protected from excessive heat and moisture, and keep out of reach of children.
Note :
TAKE THIS MEDICINE AS PER THE GUIDANCE OF HEALTHCARE PROFESSIONAL.
Keywords
